These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
129 related articles for article (PubMed ID: 38543552)
1. A Pseudovirus-Based Neutralization Assay for SARS-CoV-2 Variants: A Rapid, Cost-Effective, BSL-2-Based High-Throughput Assay Useful for Vaccine Immunogenicity Evaluation. Cai Z; Kalkeri R; Zhu M; Cloney-Clark S; Haner B; Wang M; Osman B; Dent D; Feng SL; Longacre Z; Glenn G; Plested JS Microorganisms; 2024 Feb; 12(3):. PubMed ID: 38543552 [TBL] [Abstract][Full Text] [Related]
2. Validation of a Pseudovirus Neutralization Assay for Severe Acute Respiratory Syndrome Coronavirus 2: A High-Throughput Method for the Evaluation of Vaccine Immunogenicity. Cai Z; Kalkeri R; Wang M; Haner B; Dent D; Osman B; Skonieczny P; Ross J; Feng SL; Cai R; Zhu M; Cloney-Clark S; Plested JS Microorganisms; 2024 Jun; 12(6):. PubMed ID: 38930583 [TBL] [Abstract][Full Text] [Related]
3. Developing Pseudovirus-Based Neutralization Assay against Omicron-Included SARS-CoV-2 Variants. Sun H; Xu J; Zhang G; Han J; Hao M; Chen Z; Fang T; Chi X; Yu C Viruses; 2022 Jun; 14(6):. PubMed ID: 35746803 [TBL] [Abstract][Full Text] [Related]
4. A Recombinant Protein XBB.1.5 RBD/Alum/CpG Vaccine Elicits High Neutralizing Antibody Titers against Omicron Subvariants of SARS-CoV-2. Thimmiraju SR; Adhikari R; Villar MJ; Lee J; Liu Z; Kundu R; Chen YL; Sharma S; Ghei K; Keegan B; Versteeg L; Gillespie PM; Ciciriello A; Islam NY; Poveda C; Uzcategui N; Chen WH; Kimata JT; Zhan B; Strych U; Bottazzi ME; Hotez PJ; Pollet J Vaccines (Basel); 2023 Oct; 11(10):. PubMed ID: 37896960 [TBL] [Abstract][Full Text] [Related]
5. SARS-CoV-2 Spike Pseudoviruses: A Useful Tool to Study Virus Entry and Address Emerging Neutralization Escape Phenotypes. Kalkeri R; Cai Z; Lin S; Farmer J; Kuzmichev YV; Koide F Microorganisms; 2021 Aug; 9(8):. PubMed ID: 34442823 [TBL] [Abstract][Full Text] [Related]
6. SARS-CoV-2 Variants Omicron BA.4/5 and XBB.1.5 Significantly Escape T Cell Recognition in Solid-organ Transplant Recipients Vaccinated Against the Ancestral Strain. Halvorson T; Ivison S; Huang Q; Ladua G; Yotis DM; Mannar D; Subramaniam S; Ferreira VH; Kumar D; Belga S; Levings MK; Transplantation; 2024 Apr; 108(4):e49-e62. PubMed ID: 38012843 [TBL] [Abstract][Full Text] [Related]
7. A Severe Acute Respiratory Syndrome Coronavirus 2 Anti-Spike Immunoglobulin G Assay: A Robust Method for Evaluation of Vaccine Immunogenicity Using an Established Correlate of Protection. Zhu M; Cloney-Clark S; Feng SL; Parekh A; Gorinson D; Silva D; Skonieczny P; Wilson A; Kalkeri R; Woo W; Cai MR; Fries L; Glenn G; Plested JS Microorganisms; 2023 Jul; 11(7):. PubMed ID: 37512961 [TBL] [Abstract][Full Text] [Related]
8. An Integrated Research-Clinical BSL-2 Platform for a Live SARS-CoV-2 Neutralization Assay. Zou J; Kurhade C; Chang HC; Hu Y; Meza JA; Beaver D; Trinh K; Omlid J; Elghetany B; Desai R; McCaffrey P; Garcia JD; Shi PY; Ren P; Xie X Viruses; 2023 Aug; 15(9):. PubMed ID: 37766263 [TBL] [Abstract][Full Text] [Related]
9. Deletion of the SARS-CoV-2 Spike Cytoplasmic Tail Increases Infectivity in Pseudovirus Neutralization Assays. Yu J; Li Z; He X; Gebre MS; Bondzie EA; Wan H; Jacob-Dolan C; Martinez DR; Nkolola JP; Baric RS; Barouch DH J Virol; 2021 May; 95(11):. PubMed ID: 33727331 [TBL] [Abstract][Full Text] [Related]
10. Wild-type SARS-CoV-2 neutralizing immunity decreases across variants and over time but correlates well with diagnostic testing. O'Shea KM; Schuler CF; Chen J; Troost JP; Wong PT; Chen K; O'Shea DR; Peng W; Gherasim C; Manthei DM; Valdez R; Baldwin JL; Baker JR Front Immunol; 2023; 14():1055429. PubMed ID: 36845123 [TBL] [Abstract][Full Text] [Related]
11. Immunogenicity and safety of a fourth homologous dose of NVX-CoV2373. Alves K; Plested JS; Galbiati S; Chau G; Cloney-Clark S; Zhu M; Kalkeri R; Patel N; Smith K; Marcheschi A; Pfeiffer S; McFall H; Smith G; Glenn GM; Dubovsky F; Mallory RM; Vaccine; 2023 Jun; 41(29):4280-4286. PubMed ID: 37271706 [TBL] [Abstract][Full Text] [Related]
12. Validation of a severe acute respiratory syndrome coronavirus 2 microneutralization assay for evaluation of vaccine immunogenicity. Hamilton S; Zhu M; Cloney-Clark S; Mayes P; Fenner J; Cui L; Cai R; Kalkeri R; Fries LF; Pryor M; Plested JS J Virol Methods; 2024 Jun; 327():114945. PubMed ID: 38649070 [TBL] [Abstract][Full Text] [Related]
13. Immunogenicity of convalescent and vaccinated sera against clinical isolates of ancestral SARS-CoV-2, Beta, Delta, and Omicron variants. Banerjee A; Lew J; Kroeker A; Baid K; Aftanas P; Nirmalarajah K; Maguire F; Kozak R; McDonald R; Lang A; Gerdts V; Straus SE; Gilbert L; Li AX; Mozafarihashjin M; Walmsley S; Gingras AC; Wrana JL; Mazzulli T; Colwill K; McGeer AJ; Mubareka S; Falzarano D Med; 2022 Jun; 3(6):422-432.e3. PubMed ID: 35437520 [TBL] [Abstract][Full Text] [Related]
14. XBB.1.5 spike protein COVID-19 vaccine induces broadly neutralizing and cellular immune responses against EG.5.1 and emerging XBB variants. Patel N; Trost JF; Guebre-Xabier M; Zhou H; Norton J; Jiang D; Cai Z; Zhu M; Marchese AM; Greene AM; Mallory RM; Kalkeri R; Dubovsky F; Smith G Sci Rep; 2023 Nov; 13(1):19176. PubMed ID: 37932354 [TBL] [Abstract][Full Text] [Related]
15. Exploring immune evasion of SARS-CoV-2 variants using a pseudotyped system. Duan H; Zhang E; Ren G; Cheng Y; Yang B; Liu L; Jolicoeur N; Hu H; Xu Y; Liu B Heliyon; 2024 Apr; 10(8):e29939. PubMed ID: 38699727 [TBL] [Abstract][Full Text] [Related]
16. Establishment and validation of a pseudovirus neutralization assay for SARS-CoV-2. Nie J; Li Q; Wu J; Zhao C; Hao H; Liu H; Zhang L; Nie L; Qin H; Wang M; Lu Q; Li X; Sun Q; Liu J; Fan C; Huang W; Xu M; Wang Y Emerg Microbes Infect; 2020 Dec; 9(1):680-686. PubMed ID: 32207377 [TBL] [Abstract][Full Text] [Related]